Go Pro
LON:YGEN

Yourgene Health (YGEN) Share Price, News & Analysis

Yourgene Health logo

About Yourgene Health Stock (LON:YGEN)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
13.15 million shs
Average Volume
21.98 million shs
Market Capitalization
£16.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down's syndrome, Edwards' syndrome, and Patau's Syndrome in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products. The company also offers Ranger, a technology platform for sample size selection and enrichment; Elucigene DPYD assay, a PCR test to predict a patient's response to a chemotherapy treatment; and Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for routine COVID-19 testing. In addition, it provides genomic services; sample preparation and analysis tools; and bioinformatics and software products, as well as extraction for DNA, RNA/miRNA, and nucleons; quantification; genotyping; gene expression; methylation; and microarray services for clinical research organizations. The company was formerly known as Premaitha Health PLC and changed its name to Yourgene Health Plc in November 2018. Yourgene Health Plc was incorporated in 2000 and is headquartered in Manchester, the United Kingdom. As of September 8, 2023, Yourgene Health Plc operates as a subsidiary of Novacyt UK Holdings Limited.

Receive YGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Yourgene Health and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

YGEN Stock News Headlines

Yourgene Health Launches Insight DPYD Assay
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
See More Headlines

YGEN Stock Analysis - Frequently Asked Questions

Shares of YGEN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Yourgene Health investors own include HSBC (HSBA), Imperial Brands (IMB), Antofagasta (ANTO), Avino Silver & Gold Mines (ASM), Barclays (BARC), B&M European Value Retail (BME) and BP (BP).

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
LON:YGEN
CIK
N/A
Fax
N/A
Employees
253
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
9
Net Income
-£8.17 million
Net Margins
-27.55%
Pretax Margin
N/A
Return on Equity
-27.06%
Return on Assets
-6.71%

Debt

Debt-to-Equity Ratio
68.93
Current Ratio
1.37
Quick Ratio
1.17

Sales & Book Value

Annual Sales
£29.67 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
1.53
Book Value
GBX 4 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
3,190,000,000
Free Float
N/A
Market Cap
£16.43 million
Optionable
Not Optionable
Beta
0.86
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (LON:YGEN) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners